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Background:  There have been few clinical studies on 10 mg atorvastatin as a starting dosage for treatment of hypercholesterol-
emia in type 2 diabetes mellitus (T2DM) patients. This retrospective study aims to evaluate the efficacy of 10 mg dosage of atorv-
astatin in clinical setting.
Methods:  One hundred five enrolled patients with high levels of low density lipoprotein cholesterol (LDL-C, > 100 mg/dL) took 
10 mg atorvastatin. After 6 months, they were divided into ‘Responder group’ (LDL-C < 100 mg/dL) and ‘Non-responder group’ 
(LDL-C ≥ 100 mg/dL), and the response rate was calculated. Thereafter, we subdivided the ‘Responder group’ into Maintenance 
(10 mg), Reduced dosage (5 mg), and Discontinuance group (0 mg). The ‘Non-Responder group’ was subdivided into Mainte-
nance (10 mg) and Double dosage group (20 mg). After consecutive 6 months, the response rates of each 10 mg Maintenance 
groups were compared to those of the other groups, respectively.
Results:  Following the first 6 months, the response rate of 10 mg fixed dosage was 74.3%. In the ‘Responder group’, response 
rates of 10 mg, 5 mg and Discontinuance groups following 6 months were 52.6%, 53.1%, and 12.5%, respectively. In the ‘Non-re-
sponder group’, response rates of 10 mg and 20 mg groups were 28.6% and 50.0%. Baseline LDL-C levels and body mass index 
(BMI) of ‘Responder group’ were significantly lower than those of ‘Non-responder group’ (P = 0.004, respectively).
Conclusion:  Hypercholesterolemia treatment with 10 mg, fixed dosage of atorvastatin was effective in three quarters of the sub-
jects during the first 6-month treatment; however, a significant number of patients with high LDL-C levels and/or BMI require 
higher starting and maintenance dosage.
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INTRODUCTION
Cardiovascular disease is the leading cause of death in type 2 
diabetes mellitus (T2DM) patients [1,2], and the primary cause 
of cardiovascular disease is atherosclerosis. Hypercholesterol-
emia, in turn, is a major risk factor for atherosclerosis [3].
  Hypercholesterolemia is also an important risk factor of di-
abetic retinopathy and nephropathy. Therefore, management 
of hypercholesterolemia is important in the treatment and pre-
vention of vascular complications in diabetic patients [4-6].
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  According to the National Cholesterol Education Program 
Adult Treatment Panel (NECP ATP) III guidelines proposed 
in 2001, control of low density lipoprotein cholesterol (LDL-
C) levels is considered to be the most important aim for pre-
vention of diabetic complications such as cardiovascular dis-
ease. Because T2DM is considered a cardiovascular disease 
(CVD) risk equivalent, it is recommended that LDL-C levels 
remain below 100 mg/dL in diabetic patients with hypercho-
lesterolemia [7].
  The guidelines were revised in 2004 to propose maintaining 
LDL-C levels below 70 mg/dL in patients at very high risk for 
diabetic complications [8]. Updated therapeutic guidelines 
from the Korean Society of Lipidology and Atherosclerosis 
(KSLA) proposed similar recommendations. In addition, ther-
apeutic recommendations are similar between the Korean Di-
abetes Association (KDA) and American Diabetes Association 
(ADA) [4,5,9].
  Although previous studies and guidelines from NCEP, ADA, 
and KDA have suggested overall recommendation for prescrib-
ing lipid lowering agents, or therapeutic goals, there is a lack of 
information on the practical use of lipid lowering agents, such 
as recommendations for starting dosage and dosage adjustment.
  In practice, a typical statin therapy starting and maintenance 
dosage of atorvastatin is 10 mg per day [10,11]. It is generally 
accepted that the therapeutic dosage for statins in the Asian 
population is lower than in Caucasians for control of hyper-
cholesterolemia [12,13]. Thus, we hypothesized that 10 mg 
atorvastatin dosage may be adequate as a starting and mainte-
nance dosage for control of hypercholesterolemia in T2DM 
patients.
  To verify our hypothesis, we evaluated the response rate of a 
10 mg atorvastatin fixed dosage after 6 months of treatment.
  Additionally, we wanted to know how to adjust the dosage 
when the target LDL-C levels were achieved, or not, by statin 
therapy. Thus, we compared the response rate of 10 mg atorv-
astatin treatment to the response rates for differently adjusted 
dosages, all following 6 months of treatment.
METHODS
Subjects
We evaluated the medical records of 415 T2DM patients who 
were registered at the Diabetic Center of Dong-A University 
Medical Center (DCDAMC) and had been prescribed atorvas-
tatin for treatment of hypercholesterolemia from January 2001 
to June 2008.
  Inclusion criteria for the subjects were: 1) T2DM patients 
with hypercholesterolemia (LDL-C > 100 mg/dL) who were 
managed following the lipid-lowering protocol proposed by 
the DCDAMC, and 2) patients should not have used any lipid-
lowering agents during the 2 months prior to enrollment in 
the study.
  Patients with type 1 diabetes mellitus (T1DM), baseline 
LDL-C levels above 250 mg/dL, primary hyperlipoprotein-
emia, thyroid disease, chronic liver disease such as liver cirrho-
sis, malignancy, chronic kidney disease and secondary DM 
with potential effects on their glucose and lipid metabolism, 
were excluded. T2DM patients who had developed coronary 
artery disease after 2004 also were excluded.
  Among the original 415 T2DM patients, 105 (49 males and 
56 females) met the inclusion and exclusion criteria and were 
enrolled in the study.
Methods
This is a retrospective study to evaluate the efficacy of a 10 mg 
fixed dosage of atorvastatin for treatment of hypercholesterol-
emia in T2DM patients.
  All of the enrolled patients were managed according to the 
lipid-lowering protocol of the DCDAMC.
  Atorvastatin protocol set forth by the DCDAMC for treat-
ment of hypercholesterolemia with T2DM is as follows:
 1)   Use atorvastatin 10 mg as a starting dosage and maintain 
same dosage for a maximum of 6 months.
 2)   Check fasting lipid profiles every 2 or 3 months during the 
6-month therapy period.
 3)   Responders with LDL-C levels below 100 mg/dL have 
three options for further management, at the discretion of 
their physician: A) stop taking atorvastatin, B) reduce dos-
age to 5 mg, or C) maintain the 10 mg dosage.
 4)   Non-responders with LDL-C levels above 100 mg/dL have   
two options for further management, also at the discretion 
of the physician: A) maintain a 10 mg dosage, or B) increase 
dosage to 20 mg.
All the subjects were divided into ‘Responder’ and ‘Non-re-
sponder’ after initial 6 months of therapy as the protocol.
  To evaluate the efficacy of the 6-month 10 mg atorvastatin 
treatment, we calculated the response rate, which was defined 
as the number of responders divided by the number of enrolled 
patients.
  Subjects were divided into Responder and Non-responder 361
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groups following the initial 6-month therapy period, and un-
derwent an additional 6 months of treatment per the options 
set forth in the protocol. Following the second 6 month thera-
py period, the ‘Responder group’ was divided into two sub-
groups, a Remission maintenance group and a Remission 
maintenance failure group, according to plasma levels of LDL-
C (Fig. 1). Remission was defined as final LDL-C levels main-
tained below 100 mg/dL. We then examined the response rates 
for each subgroup.
  The ‘Non-responder group’ was also further divided into 
two subgroups: a Delayed remission group and Remission 
failure group (Fig. 1). We then calculated the response rate for 
each subgroup.
  To evaluate the long-term efficacy of the 10 mg atorvastatin 
dosage, we examined response rates in a 5 year follow-up.
  We hypothesized that the response rate would be different 
according to baseline LDL-C levels and body mass index (BMI). 
Thus, we stratified the patients by baseline LDL-C levels and 
BMI and compared the response rate for each group following 
the initial 6-month therapy period.
  We collected clinical and laboratory data (DM duration, 
baseline LDL-C, HbA1c, and C-peptide levels, smoking history, 
hypertension, gender, body weight, height and baseline BMI) 
from the medical records and compared the data between Re-
sponder and Non-responder groups. We compared the clini-
cal characteristics between the Remission maintenance group 
and the Remission maintenance failure group. We also com-
pared the clinical characteristics between the Remission main-
tenance group of ‘Responder group’ and Remission failure 
group of ‘Non-responder group’.
  We selected plasma LDL-C levels as a parameter to assess 
the efficacy of atorvastatin treatment. Data on baseline and 
follow-up LDL-C levels were collected from medical records. 
LDL-C levels were checked every 2 to 3 months according to 
DCDAMC protocol.
Statistical analysis
Results of our statistical analyses are expressed as the mean 
and standard deviation, or as percentage, and were calculated 
using the statistical software package SPSS version 17.0 for 
Windows (SPSS Inc., Chicago, IL, USA). Baseline demograph-
ics and clinical characteristics were analyzed using mean by 
frequency analysis, compare means with independent samples 
t-test. Cross tabulation analysis was used to evaluate patients 
response to atorvastatin and progression profiles. We exam-
ined the relationship between LDL-C levels and BMI by corre-
lation analysis. Statistical significance was established as a P 
value less than 0.05.
RESULTS
Baseline demographics and clinical characteristics of the 
study subjects
Among the 105 enrolled patients, there were 49 men (46.7%) 
Fig. 1.  Schematic flow diagram of study setting: 105 patients with type 2 diabetes mellitus (T2DM) underwent atorvastatin 10 
mg therapy as starting dose for reducing high low density lipoprotein cholesterol (LDL-C) levels (> 100 mg/dL) were enrolled for 
the study. After 6 months of treatment, the subjects were divided into a responder group (LDL-C < 100 mg/dL) or Non-Respond-
er group (LDL-C ≥ 100 mg/dL). Thereafter, the Responder group was subdivided into a Remission maintenance group and Re-
mission maintenance failure group. The Non-responder group was subdivided into a Delayed remission group and Remission 
failure group. Dosage modifications were made following a response to each dosage of atorvastatin.
Responder group  
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and 56 women (53.3%).
  The mean subject age was 54 ± 8 years, mean DM duration 
was 6 ± 5 years, mean baseline LDL-C level was 151 ± 21 mg/
dL, mean HbA1c level was 8.0 ± 1.4%, and mean BMI was 
24.9 ± 2.8 (Table 1).
  Forty-three patients (41.0%) had hypertension and 20 pa-
tients (19.0%) had a history of smoking (data not shown).
Response rate following initial 6-month therapy period 
with 10 mg atorvastatin
Among the 105 patients, 78 patients had plasma LDL-C levels 
below 100 mg/dL following 6 months of therapy and were 
placed in the ‘Responder group’. Thus, the response rate was 
74.3%. Twenty-seven patients were placed in the ‘Non-re-
sponder group’.
Comparison of baseline demographics and clinical 
characteristics of the Responder and Non-responder group 
following the initial 6-month therapy period
Among several parameters that were evaluated, only baseline 
LDL-C levels and BMI were significantly lower in the ‘Respond-
er group’ than in the ‘Non-responder group’ (P = 0.004, respec-
tively). Unexpectedly, age, DM duration, and baseline HbA1c 
levels were not statistically significant factors (Table 2).
  Although, the proportion of hypertensive patients was low-
er in the ‘Responder group’ (n = 29, 37.2%) than in the ‘Non-
responder group’ (n = 14, 59.9%), there was no statistical sig-
nificance between them. The proportion of patients with a 
smoking history was similar in the ‘Responder group’ (n = 15, 
19.2%) and ‘Non-responder group’ (n = 5, 18.5%); however, 
this was also shown to be statistically insignificant.
Response rates in the ‘Responder group’ for the 3 dosage 
adjustment regimens following the additional 6-month 
therapy period
Dosages were adjusted according to the response measured 
following the initial 6 months of therapy, and LDL-C levels 
were again measured following an additional 6 months of 
therapy.
  In the second 6-month therapy period, the ‘Responder group’ 
was either administered a 10 mg maintenance dosage (10 mg 
group), a half dosage atorvastatin (5 mg group), or medication 
was discontinued (Discontinuance group), as per DCDAMC 
protocol. The response rates, based on the reference LDL-C 
level of 100 mg/dL, were 52.6% in the 10 mg group (n = 20 of 
38), 53.1% in the 5 mg group (n = 17 of 32), and 12.5% in the 
Discontinuance group (n = 1 of 8) (Table 3).
Response rates in the ‘Non-responder group’ for the 2 
dosage adjustment regimens following the additional 6 
months of therapy
The ‘Non-responder group’ received either a 10 mg mainte-
nance dosage (10 mg group) or double dosage (20 mg group) 
for 6 months following the initial 6-month therapy period, per 
DCDAMC protocol. The response rates were 28.6% in the 
Table 2.  Demographics and clinical characteristics of re-
sponder and non-responder groups following 6 months of 
therapy
Characteristic
Total (n = 105)
Responder
(n = 78, 74.3%)
Non- 
responder
(n = 27, 25.7%)
P value
Age, yr 54 ± 9 54 ± 7 0.947
DM duration, yr 6 ± 5 7 ± 5 0.302
Baseline LDL-C, mg/dL 146 ± 17 163 ± 27 0.004
HbA1c, % 8.2 ± 1.5 7.7 ± 1.2 0.151
Insulin, μIU/mL 6.77 ± 6.07 7.58 ± 6.10 0.553
C-peptide, ng/mL 2.17 ± 1.15 1.91 ± 1.01 0.263
Weight, kg 65 ± 10 67 ± 9 0.231
Height, m 1.62 ± 0.07 1.60 ± 0.08 0.148
Body mass index, kg/m
2 24.5 ± 2.7 26.2 ± 2.5 0.004
Values are presented as mean ± standard deviation. 
DM, diabetes mellitus; LDL-C, low density lipoprotein cholesterol.
Table 1.  Demographics and clinical characteristics of the 
study subjects
Characteristic
Total (n = 105)
Mean ± SD Range
Age, yr 54 ± 8 20-70
DM duration, yr 6 ± 5 0-21
Baseline LDL-C, mg/dL 151 ± 21 111-224
HbA1c, % 8.0 ± 1.4 5.9-12.3
Insulin, μIU/mL 6.98 ± 6.06 0.04-35.40
C-peptide, ng/mL 2.11 ± 1.12 0.05-5.42
Weight, kg 65 ± 10 47-103
Height, m 1.62 ± 0.07 1.46-1.81
Body mass index, kg/m
2 24.9 ± 2.8 19.5-36.5
SD, standard deviation; DM, diabetes mellitus; LDL-C, low density li-
poprotein cholesterol.363
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Maintenance dosage (n = 6 of 21) and 50.0% in the Double 
dosage group (n = 3 of 6) (Table 3).
Comparison of baseline demographics and clinical 
characteristics of each subgroup following the additional 6 
months of therapy
We compared clinical characteristics between the Remission 
maintenance group and Remission maintenance failure group 
and found no significant differences between the two groups 
(Table 4).
  We also compared clinical characteristics between the Re-
mission maintenance group and Remission failure group. We 
found that in the Remission maintenance group, LDL-C levels 
and BMI were lower than those of the Remission failure group, 
with significance (Table 5).
Response rates in the long-term follow-up: 5 years after 
initial therapy period
Among all enrolled patients, the 5-year long term follow-up 
was conducted on 28 patients. Some changes in dosage had 
Table 3.  Responses following 12 months of therapy
Responder
(n = 78)
Dosage after 6 mo
Response after 12 mo
P value Remission  
maintenance group
Remission maintenance 
failure group
Remission  
maintenance rate (%)
Stop (n = 8) 1 7 12.5
5 mg (n = 32) 17 15 53.1 0.096
10 mg (n = 38) 20 18 52.6
Total 38 40 48.7
Non-
responder
(n = 27)
Dosage after 6 mo
Response after 12 mo
P value
Delayed remission group Remission failure group Delayed remission rate (%)
10 mg (n = 21) 6 15 28.6
20 mg (n = 6) 3 3 50 0.326
Total 9 18 33.3
SD, standard deviation; DM, diabetes mellitus; LDL-C, low density lipoprotein cholesterol.
Table 4.  Clinical characteristics of remission maintenance 
group and remission maintenance failure group in responder 
group following 12 months of therapy
Characteristic
Total (n = 78)
Remission 
maintenance 
group 
(n = 38)
Remission 
maintenance 
failure group 
(n = 40)
P value
Age, yr 55 ± 8 53 ± 9 0.274
DM duration, yr 6 ± 5 6 ± 5 0.851
Baseline LDL-C, mg/dL 143 ± 17 150 ± 17 0.087
HbA1c, % 8.3 ± 1.6 8.0 ± 1.4 0.313
Insulin, μIU/mL 6.20 ± 6.62 7.32 ± 5.52 0.421
C-peptide, ng/mL 2.21 ± 1.25 2.13 ± 1.07 0.779
Weight, kg 63 ± 8 66 ± 11 0.214
Height, m 1.62 ± 0.07 1.62 ± 0.07 0.867
Body mass index, kg/m
2 23.9 ± 2.2 25.0 ± 3.2 0.098
Values are presented as mean ± standard deviation.
DM, diabetes mellitus; LDL-C, low density lipoprotein cholesterol.
Table 5.  Clinical characteristics of Remission maintenance 
group in Responder group and Remission failure group in 
Non-responder following 12 months of therapy
Characteristic
Total (n = 56)
Remission 
maintenance 
group (n = 38) 
Remission 
failure group 
(n = 18)
P value
Age, yr 55 ± 8 54 ± 7 0.698
DM duration, yr 6 ± 5 6 ± 4 0.723
Baseline LDL-C, mg/dL 143 ± 17 161 ± 27 0.016
HbA1c, % 8.3 ± 1.6 7.8 ± 1.3 0.227
Insulin, μIU/mL 6.20 ± 6.62 8.23 ± 6.50 0.287
C-peptide, ng/mL 2.21 ± 1.25 2.11 ± 1.13 0.765
Weight, kg 63 ± 8 68 ± 9 0.059
Height, m 1.62 ± 0.07 1.61 ± 0.08 0.440
Body mass index, kg/m
2 23.9 ± 2.2 26.1 ± 2.6 0.001
Values are presented as mean ± standard deviation.
DM, diabetes mellitus; LDL-C, low density lipoprotein cholesterol.364
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occurred in 20 of the patients; however, all 28 patients were 
administered 10 mg atorvastatin during the 3 months imme-
diately preceding the 5-year follow-up evaluation.
  Of the 28 patients, 20 patients had LDL-C levels below 100 
mg/dL, yielding an overall response rate of 71.4%.
  In addition, among these 28 patients, 8 patients had been 
administered 10 mg atorvastatin as a starting and mainte-
nance dosage without any change in dosage for the entire 5 
years. Seven of those patients had final LDL-C levels below 100 
mg/dL; therefore, the 5-year response rate in that group was 
87.5% (Fig. 2).
Correlation between statistically significant risk factors
Baseline LDL-C levels and baseline BMI were the risk factors 
which influenced the response rate following 6 months of 
therapy. There was significant correlation between these two 
risk factors, and the correlation coefficient was 0.251 (P = 0.01) 
(Fig. 3).
Six-month therapy response by baseline LDL-C levels and 
BMI
As the significant risk factors among the baseline clinical char-
acteristics were baseline LDL-C levels and BMI, we classified 
the subjects into 3 subgroups according to baseline LDL-C 
level (< 130 mg/dL, 130-160 mg/dL, and ≥ 160 mg/dL). Re-
sponse rates following the initial 6-month therapy period were 
100%, 72.7%, and 66.7%, respectively (Table 6).
  In addition, we also classified the enrolled patients by their 
WHO BMI classification category. They were divided into 4 
categories: baseline BMI (kg/m
2) < 18.5 (underweight), 18.5 ≤ 
baseline BMI (kg/m
2) < 25 (normal), 25 ≤ baseline BMI (kg/
m
2) < 30 (overweight), and baseline BMI (kg/m
2) ≥ 30 (obese). 
None of the patients had a baseline BMI below 18.5. Following 
the initial 6-month therapy period, the responses rates for 
these groups were 86.4%, 59.5%, and 50% for the normal, 
overweight, and obese groups, respectively (Table 7).
DISCUSSION
In this study, we found that the response rate to an initial 
Table 6.  Response rate according to stratification by baseline 
LDL-C level following 6 months of therapy
Baseline LDL-C level,  
mg/dL
Responder 
group 
(n = 78)
Non- 
responder 
group 
(n = 27)
Response 
rate (%)
< 130 (n = 12) 12 0 100
130 to 160 (n = 66) 48 18 72.7
≥ 160 (n = 27) 18 9 66.7
LDL-C, low density lipoprotein cholesterol.
Fig. 3. Correlation between baseline low density lipoprotein 
cholesterol (LDL-C) levels and body mass index (BMI) (two 
significant risk factors for short-term non-response).There 
was significant correlation between these two risk factors. The 
correlation coefficient was 0.251 (P = 0.01).
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6-month therapy period with atorvastatin 10 mg was 74.3%. 
This result is very similar to the 75.5% response rate report by 
Pola et al. [14], but higher than the 59% reported by Aguilar-
Salinas et al. [11]. Aguilar-Salinas’ study, inclusion criteria of 
enrolled patients was an LDL-C level above 130 mg/dL, which 
was higher than that of our study (above 100 mg/dL).
  We found that baseline LDL-C levels and BMI were signifi-
cantly lower in the ‘Responder group’ than in the ‘Non-re-
sponder group’, following the initial 6-month therapy period. 
This result on LDL-C levels is supported by other reports [15].
Patients with high BMI showed a poor response to the usual 
dosage of atorvastatin. We demonstrated a significant correla-
tion between baseline LDL-C level and baseline BMI; however, 
the correlation was not strong. If a poor response in patients 
with high BMI is independent of LDL-C level, the explanation 
might be simple: a greater fat mass may require a greater 
amount of statin. However, this explanation need to be further 
studied and clarified.
  The clinical implication of our result is clear: patients with 
high LDL-C levels and/or high BMI should start treatment with 
a higher initial dosage of atorvastatin.
  Among our subjects were patients with moderate to severe 
hypercholesterolemia. From the view point of current consen-
sus for statin treatment, this group of patients was not indicat-
ed for 10 mg atorvastatin treatment. If this group of patients 
had been excluded from this study, nearly all patients would 
have shown good response rate.
  Nevertheless, the wide range of subjects and results of this 
study are meaningful, as this group of patients represents the 
typical range of patients who we meet every day in our clinic. 
Our results suggest that three quarters of the patients whom 
we care for will be responsive to 10 mg fixed atorvastatin dos-
age and will reach target LDL-C goals. The quarter of patients 
with high baseline LDL-C levels and/or high BMI need a high-
er dosage of atorvastatin. If we had excluded the group of pa-
tients with moderate to severe hypercholesterolemia from our 
study, we would not have found the results nearly as useful for 
our practice.
  Guidelines for conditioning therapy in the long term follow-
ing successful control of LDL-C with lipid-lowering agents have 
yet to be established and maintaining the same dosage of medi-
cation is the customary practice.
  We compared the response rates between the Half-dosage 
group and Discontinuance group following the additional 6 
months of therapy. The response rate was 53.1% in the Half-
dosage group, which is similar to reports by others [15]. Even 
though the response rate of the Half-dosage group is better 
than that of the Discontinuance group, we do not recommend 
these kinds of dosage adjustments.
  It was unexpected that, in the ‘Responder group’, LDL-C 
levels increased again to above 100 mg/dL in 47.4% of the 10   
mg Maintenance group.
  There may be several possible causes for this high rate of 
maintenance failure. First, the subjects may not have regularly 
taken their medication. Second, lifestyle modifications may 
not have been maintained successfully. Third, there may be a 
secondary failure of atorvastatin.
  Dosage up-titration is a common practice with non-respon-
sive patients. We compared the response rates of the 10 mg 
Maintenance group and 20 mg Double dosage group. The re-
sponse rate of Double dosage group (50.0%) was better than 
that of the Maintenance group (28.6%).
  We infer that it is necessary to increase the dosage of atorv-
astatin by at least double for the ‘Non-responder group’. More-
over, if patients do not show a response to a 20 mg dosage, they 
may need to increase to the maximal dosage of atorvastatin 
monotherapy [7,8], and a prompt up-titration should also be 
applied [11,16].
  If patients continue to show failure of lipid control with the 
higher dosage of atorvastatin or experience significant side ef-
fects, we should consider adding other lipid lowering agents, 
such as ezetimibe [17-19].
  Under these conditions, it may be worthwhile to investigate 
whether the patients had primary dyslipidemia or not; howev-
er, we did not perform this evaluation.
  The 5-year follow-up data from this study are promising. 
Even though the number of patients in our study was too small 
to draw a certain conclusions, in does appear that long-term 
use of atorvastatin has a favorable lipid-lowering effect. The 
Table 7.  Response rate according to stratification by BMI and 
WHO classification following 6 months of therapy
BMI, kg/m
2
Responder 
group 
(n = 78)
Non- 
responder 
group 
(n = 27)
Response 
rate (%)
18.5 to 24.9 (n = 59) 51 8 86.4
25 to 29.9 (n = 42) 25 17 59.5
≥ 30 (n = 4) 2 2 50.0
No patients had a baseline BMI below 18.5.
BMI, body mass index; WHO, World Health Organization.366
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5-year LDL-C profiles of the 8 cases who took a 10 mg fixed 
dosage of atorvastatin during the entire period give us the in-
sight that final LDL-C levels within the target range are achiev-
able long-term, even though some fluctuations in LDL-C lev-
els were noted during that period. The fluctuations in LDL-C 
levels seem to be related to compliance of the individual pa-
tient rather than the efficacy or dosage of medication (Fig. 2). 
We could exclude other possibilities such as the effect of con-
comitantly using medications or episodes of other diseases.
  The results of our study are comparable to those of the Ste-
no-2 study, although that study was on total cholesterol, not 
LDL-C. Nonetheless, the Steno-2 study also showed that about 
80% of subjects were controlled. In that study, however, the 
lipid lowering therapy was more intensive and applied for a 
longer period than in our study. The lipid lowering agent in 
the Steno-2 study was also atorvastatin, with a maximum dos-
age of 80 mg daily, or the equivalent, and the study duration 
was 7.8 years [20]. 
  If our results are reliable, we could hypothesize that long-
term therapy with atorvastatin for diabetic patients can bring 
more favorable results in the control of LDL-C levels, even 
though prompt up-titrations were not applied. This is not the 
same concept as the legacy effect or metabolic memory. We 
hypothesized that long-term statin use decreases the size of 
the LDL-C pool, induces a decrease in serum LDL-C, and helps 
to maintain stable lipid levels.
  This study has some limitations. First, the number of patients 
that followed the DCDAMC lipid lowering protocol was in-
sufficient for us to enroll enough subjects, and this may add 
bias to our study. Second, we could not confirm that the pre-
scribed lifestyle modifications associated with diet or exercise 
were performed. This may also have an effect on our results. 
Third, medical compliance by the enrolled patients was not 
guaranteed. Finally, medication history from other clinics with-
in at least 2 months prior to study initiation was not fully iden-
tified, which may have resulted in under-estimation of the base-
line or final LDL-C levels.
  In conclusion, routine 10 mg fixed dosage atorvastatin ther-
apy is effective in about three quarters of T2DM subjects for 
treatment of hypercholesterolemia, during the first 6 months 
of therapy.
  However, patients with high baseline LDL-C levels and high 
BMI may need a higher starting and maintenance dosage or 
even other therapeutic regimens, for better control. 
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